Home Newsfeeds Watching Imunon, Zacks Small-Cap Research Sets $17 Price Valuation

Watching Imunon, Zacks Small-Cap Research Sets $17 Price Valuation

https://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Research_11302022_IMNN_Bautz.pdf

byBenzinga Newsdesk

November 30, 2022

1 minute read

https://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Research_11302022_IMNN_Bautz.pdf

Wells Fargo Maintains Equal-Weight on Equifax, Raises Price Target to $210

By Benzinga Newsdesk

January 13, 9:09 AM

Wells Fargo analyst Seth Weber maintains Equifax (NYSE:EFX) with a Equal-Weight and raises the price target from $165 to $210.

EFX

Anavex Life Sciences Announces Late-Breaking Presentation Of Phase 2b/3 Data of Oral ANAVEX 2-73 (blarcamesine) For Early Alzheimer’s Disease At Upcoming Clinical Trials On Alzheimer’s Disease (CTAD) Congress 2022

By Bill Haddad

October 17, 7:04 AM

Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and

AVXL

Does Google Compete In Search With General Motors, Yelp, Amazon And Even The DC Federal Court — Defense Expert In AntiTrust Case Testifies

By Benzinga Neuro

November 6, 11:25 PM

An economist testifies that Google's online search competition includes a diverse range of companies, like Amazon and Yelp, challenging the Department of Justice's narrow view of Google's market dominance in the antitrust trial.

AMZN

Safe Harbor Financial Q1 Revenue Grows 150% YoY, Surpasses $1.1B In Quarterly Deposits

By Joana Scopel

May 15, 9:04 PM

On Monday, SHF Holdings, Inc., d/b/a/ Safe Harbor Financial (NASDAQ: SHFS), announced its financial results for the quarter ended March 31, 2023, revealing net revenue of $4.2 million in Q1 2023, an increase of 150% compared to $1.7 million in Q1 2022.

FISI

Watching Imunon, Zacks Small-Cap Research Sets $17 Price Valuation

Related Posts

Wells Fargo Maintains Equal-Weight on Equifax, Raises Price Target to $210

Anavex Life Sciences Announces Late-Breaking Presentation Of Phase 2b/3 Data of Oral ANAVEX 2-73 (blarcamesine) For Early Alzheimer’s Disease At Upcoming Clinical Trials On Alzheimer’s Disease (CTAD) Congress 2022

Does Google Compete In Search With General Motors, Yelp, Amazon And Even The DC Federal Court — Defense Expert In AntiTrust Case Testifies

Safe Harbor Financial Q1 Revenue Grows 150% YoY, Surpasses $1.1B In Quarterly Deposits